Several antigens or glioma specific molecules have been characterized and utilized in glioma vaccines, including epidermal growth factor receptor variant III (EGFRvIII), IL-13 receptor α2, IL-4 receptor, and heat shock protein (HSP) gp96 (Eguchi et al., 2006; Graner et al., 2007; Kawakami et al., 2000; Li et al., 2010). The gene discussed is HSP90B2P; the disease is central nervous system cancer.